![Jayson Rieger](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jayson Rieger
Directeur Général chez
VERRICA PHARMACEUTICALS INC.
Fortune : 1 M $ au 31/05/2026
Profil
Jayson M.
Rieger is President, Chief Executive Officer & Director at Verrica Pharmaceuticals, Inc. since 2024.
Dr. Rieger is Director at Xalud Therapeutics, Inc. Dr. Rieger is Managing Partner at PBM Capital Group LLC since 2014.
Former roles include Chief Operating Officer & Director at Verrica Pharmaceuticals, Inc. from 2015 to 2018, Director at Lytix Biopharma ASA, Senior VP & President-Human Therapeutics at Precigen, Inc. from 2012 to 2013, Vice President-Research & Virginia Operations at Clinical Data, Inc. from 2008 to 2011, and Vice President-Lead Development & Manufacturing at Adenosine Therapeutics LLC from 2002 to 2008.
Education includes a doctorate from the University of Virginia, an undergraduate degree from Rollins College (Florida), and an MBA from the University of Virginia Darden School of Business.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 05/06/2026 | 183 298 ( 1,07 % ) | 1 M $ | 31/05/2026 |
Postes actifs de Jayson Rieger
| Sociétés | Poste | Début |
|---|---|---|
| VERRICA PHARMACEUTICALS INC. | Directeur Général | 05/11/2024 |
Xalud Therapeutics, Inc.
 Xalud Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company advancing a non-viral plasmid DNA delivered gene therapy platform to treat pathologic inflammation | Directeur/Membre du Conseil | - |
PBM Capital Group LLC
 PBM Capital Group LLC Investment ManagersFinance PBM Capital Group invests in companies located in the United States. The firm targets companies operating in the fields of pharmaceutical and life sciences industries. They provide financing for buyout and early stage capital requirements. | Private Equity Investor | 01/03/2014 |
Anciens postes connus de Jayson Rieger
| Sociétés | Poste | Fin |
|---|---|---|
| VERRICA PHARMACEUTICALS INC. | Directeur des opérations | - |
| PRECIGEN, INC. | Corporate Officer/Principal | 01/08/2013 |
Clinical Data, Inc.
 Clinical Data, Inc. Medical SpecialtiesHealth Technology Manufactures and distributes scientific instruments | Corporate Officer/Principal | 01/01/2011 |
Adenosine Therapeutics LLC
 Adenosine Therapeutics LLC Pharmaceuticals: MajorHealth Technology Manufactures and develops pharmaceutical products | Corporate Officer/Principal | 01/01/2008 |
| LYTIX BIOPHARMA ASA | Directeur/Membre du Conseil | - |
Formation de Jayson Rieger
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
18
Relations au 1er degré
10
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 10 |
|---|---|
Clinical Data, Inc.
Clinical Data, Inc. Medical SpecialtiesHealth Technology Manufactures and distributes scientific instruments | Health Technology |
Adenosine Therapeutics LLC
Adenosine Therapeutics LLC Pharmaceuticals: MajorHealth Technology Manufactures and develops pharmaceutical products | Health Technology |
Precigen, Inc.
 Precigen, Inc. BiotechnologyHealth Technology Operates as clinical-stage biopharmaceutical company | Health Technology |
University of Virginia
 University of Virginia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Rollins College (Florida)
 Rollins College (Florida) Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Lytix Biopharma AS
 Lytix Biopharma AS Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biotechnology company that develops novel cancer immunotherapies | Health Technology |
PBM Capital Group LLC
PBM Capital Group LLC Investment ManagersFinance PBM Capital Group invests in companies located in the United States. The firm targets companies operating in the fields of pharmaceutical and life sciences industries. They provide financing for buyout and early stage capital requirements. | Finance |
University of Virginia Darden School of Business
 University of Virginia Darden School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Xalud Therapeutics, Inc.
Xalud Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company advancing a non-viral plasmid DNA delivered gene therapy platform to treat pathologic inflammation | Health Technology |
Verrica Pharmaceuticals, Inc.
 Verrica Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
